Evolus Inc (NASDAQ:EOLS) Short Interest Update

Evolus Inc (NASDAQ:EOLS) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 5,700,000 shares, a growth of 11.8% from the December 15th total of 5,100,000 shares. Based on an average trading volume of 553,500 shares, the days-to-cover ratio is currently 10.3 days. Approximately 25.6% of the company’s shares are short sold.

In other Evolus news, insider Rui Avelar sold 39,442 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $10.71, for a total value of $422,423.82. Following the completion of the sale, the insider now directly owns 70,802 shares of the company’s stock, valued at approximately $758,289.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.90% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. boosted its position in shares of Evolus by 2,224.0% during the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,324 shares of the company’s stock worth $34,000 after acquiring an additional 2,224 shares in the last quarter. Metropolitan Life Insurance Co NY purchased a new position in Evolus during the 1st quarter worth approximately $83,000. Royal Bank of Canada increased its position in Evolus by 429.1% during the second quarter. Royal Bank of Canada now owns 4,365 shares of the company’s stock worth $64,000 after buying an additional 3,540 shares during the period. California Public Employees Retirement System acquired a new position in Evolus during the third quarter worth approximately $163,000. Finally, UBS Asset Management Americas Inc. purchased a new stake in Evolus in the second quarter valued at approximately $156,000. 16.94% of the stock is owned by institutional investors and hedge funds.

EOLS has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Evolus in a research report on Tuesday, November 5th. Svb Leerink initiated coverage on Evolus in a research report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective for the company. Zacks Investment Research raised Evolus from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th. ValuEngine raised Evolus from a “hold” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Leerink Swann initiated coverage on Evolus in a research report on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $26.36.

Shares of NASDAQ:EOLS traded up $0.12 on Thursday, hitting $11.12. 10,804 shares of the company’s stock were exchanged, compared to its average volume of 675,165. The firm’s 50-day moving average is $12.19 and its 200 day moving average is $14.93. The company has a market capitalization of $366.67 million, a PE ratio of -7.07 and a beta of 4.24. Evolus has a 1-year low of $10.31 and a 1-year high of $30.25. The company has a debt-to-equity ratio of 4.53, a quick ratio of 3.28 and a current ratio of 3.66.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Monday, November 4th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.33) by $0.55. The business had revenue of $13.17 million for the quarter, compared to analyst estimates of $5.18 million. On average, analysts anticipate that Evolus will post -3.75 EPS for the current fiscal year.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Featured Story: Treasury Bonds

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.